Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹3,911 Cr
up ₹258 Cr vs Aug 2020
- Stocks held
- 21
- up 1 vs Aug 2020
- Top 10 weight
- 76.7%
- of the portfolio in its ten largest
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In September 2020 it disclosed 21 stocks worth ₹3,911 Cr, up ₹258 Cr from Aug 2020. Its largest positions were Lupin Limited (10.3%), Aurobindo Pharma Limited (10.0%), Sun Pharmaceutical Industries Limited (9.7%); the ten largest together made up 76.7% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 79.0% of its equity. Cash and debt stood at 3.2%. Compared with Aug 2020 the fund entered 3 new stocks and exited 2.
Against 229 other Sectoral / Thematic funds
Concentration
96%
Top-10 weight is higher than 96% of peers
Breadth
6%
Holds more stocks than 6% of peers
Cash
46%
Holds more cash than 46% of peers
What these mean: concentration · cash
Holdings in September 2020
Download CSVEvery line the fund disclosed, with the change against Aug 2020. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Lupin Limited | 10.30% | up 0.15 pts | ₹403 Cr | up ₹31.9 Cr | Added |
| Aurobindo Pharma Limited | 10.00% | up 0.48 pts | ₹391 Cr | up ₹43.3 Cr | Added |
| Sun Pharmaceutical Industries Limited | 9.73% | down 0.53 pts | ₹380 Cr | up ₹5.8 Cr | Added |
| Dr. Reddy's Laboratories Limited | 9.62% | up 0.16 pts | ₹376 Cr | up ₹30.7 Cr | Added |
| Divi's Laboratories Limited | 9.35% | down 0.91 pts | ₹366 Cr | down ₹9 Cr | Trimmed |
| Cipla Limited | 9.31% | up 0.13 pts | ₹364 Cr | up ₹28.7 Cr | Added |
| Thyrocare Technologies Limited | 5.54% | down 0.28 pts | ₹216 Cr | up ₹4.1 Cr | Added |
| Fortis Healthcare Limited | 4.98% | down 0.25 pts | ₹195 Cr | up ₹3.6 Cr | Added |
| Zydus Lifesciences Limited | 4.04% | down 0.02 pts | ₹158 Cr | up ₹9.5 Cr | Added |
| Sanofi India Limited | 3.87% | down 0.07 pts | ₹151 Cr | up ₹7.4 Cr | Added |
| Abbott India Limited | 3.56% | down 0.04 pts | ₹139 Cr | up ₹7.8 Cr | Added |
| Narayana Hrudayalaya Limited | 3.55% | up 0.31 pts | ₹139 Cr | up ₹20.3 Cr | Added |
| Cash, TREPS & receivables | 3.25% | down 0.16 pts | ₹127 Cr | up ₹2.4 Cr | Added |
| Biocon Limited | 2.87% | up 0.29 pts | ₹112 Cr | up ₹17.9 Cr | Added |
| Indoco Remedies Limited | 2.22% | up 0.18 pts | ₹86.9 Cr | up ₹12.5 Cr | Added |
| Syngene International Limited | 2.12% | down 1.77 pts | ₹83.1 Cr | down ₹59.3 Cr | Trimmed |
| Shilpa Medicare Limited | 1.79% | up 1.79 pts | ₹70 Cr | up ₹70 Cr | New |
| Apollo Hospitals Enterprise Limited | 1.61% | up 1.61 pts | ₹62.8 Cr | up ₹62.8 Cr | New |
| Alkem Laboratories Limited | 0.78% | down 0.04 pts | ₹30.4 Cr | up ₹61 L | Added |
| Pfizer Limited | 0.66% | up 0.04 pts | ₹25.8 Cr | up ₹3.3 Cr | Added |
| Torrent Pharmaceuticals Limited | 0.54% | up 0.54 pts | ₹21 Cr | up ₹21 Cr | New |
| Healthcare Global Enterprises Limited | 0.32% | down 0.03 pts | ₹12.6 Cr | down ₹13 L | Trimmed |
What changed, Aug 2020 to Sep 2020
New New positions (3)
- Shilpa Medicare Limited1.8% · ₹70 Cr
- Apollo Hospitals Enterprise Limited1.6% · ₹62.8 Cr
- Torrent Pharmaceuticals Limited0.5% · ₹21 Cr
Exited Exited (2)
- Laurus Labs Limitedwas 1.2% · ₹45.3 Cr
- GlaxoSmithKline Pharmaceuticals Limitedwas 0.3% · ₹11.8 Cr
Added Biggest additions
- Aurobindo Pharma Limitedup ₹43.3 Cr (+0.48% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Aug 2020, the weight rose most in Pharmaceuticals & Biotechnology (+0.3 pts) and Pharmaceuticals (+0.2 pts), and fell most in Healthcare Services (−0.5 pts).
- Pharmaceuticals & Biotechnology78.7% → 79.0%+0.3 pts
- Pharmaceuticals2.1% → 2.3%+0.2 pts
- Healthcare Services19.2% → 18.7%−0.5 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Sep 2019 | Mar 2020 | Jun 2020 | Aug 2020 | Sep 2020 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 78.9% | 78.4% | 78.0% | 78.7% | 79.0% |
| Healthcare Services | 20.3% | 19.4% | 19.9% | 19.2% | 18.7% |
| Pharmaceuticals | 0.7% | 2.2% | 2.2% | 2.1% | 2.3% |
Allocation in Sep 2020change vs Aug 2020
- Pharmaceuticals & Biotechnology (14)79.0%▲ 0.3 pts
- Healthcare Services (6)18.7%▼ 0.5 pts
- Pharmaceuticals (1)2.3%▲ 0.2 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Sep 2020
3.2%
▼ 0.2 pts vs Aug 2020
- Cash alone
- 3.2%
- cash and net receivables
- A year earlier
- 0.2%
- Sep 2019 · now ▲ 3.0 pts
- Last 12 months
- −<0.1% – 4.5%
- lowest to highest · record 4.5% in Jul 2020
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.